تاريخ الإيرادات والأرباح والتدفقات النقدية من القوائم المالية الرسمية.
Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia, as well as offers products under the name of ALKINDI and Efmody.
الرسوم البيانية التفاعلية والقوائم الكاملة ← نموذج التقييم (DCF) ←
| قائمة الدخل | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| إجمالي الإيرادات | $3.4B | $2.9B | $2.4B | $1.9B | $1.5B | $1.1B | $1.0B | $788M | $451M | $162M | $15M | $20M | $0M | $3M | $53M | $77M | $34M | $3M | $4M | $1M | $39M |
| إجمالي الربح | $3.3B | $2.8B | $2.3B | $1.8B | $1.5B | $1.1B | $1.0B | $781M | $446M | $160M | $15M | $20M | ($14M) | ($11M) | $42M | $77M | $34M | $3M | $4M | $1M | $39M |
| هامش الربح الإجمالي % | 98.0% | 98.2% | 98.6% | 97.9% | 98.4% | 98.7% | 99.0% | 99.1% | 98.9% | 99.2% | 100.0% | 100.0% | — | -372.8% | 78.2% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| الدخل التشغيلي (EBIT) | $789M | $619M | $570M | $251M | $249M | $102M | $163M | $72M | $37M | ($131M) | ($147M) | ($94M) | ($64M) | ($50M) | $1M | $34M | ($14M) | ($54M) | ($87M) | ($212M) | ($113M) |
| هامش التشغيل % | 23.4% | 21.6% | 24.2% | 13.3% | 16.7% | 9.0% | 15.6% | 9.2% | 8.2% | -81.3% | -982.5% | -476.5% | — | -1701.9% | 2.7% | 43.8% | -41.0% | -1817.5% | -2196.2% | -17340.0% | -288.8% |
| صافي الدخل | $706M | $479M | $341M | $250M | $154M | $90M | $407M | $37M | $21M | ($143M) | ($141M) | ($89M) | ($61M) | ($46M) | $5M | $38M | ($8M) | ($51M) | ($89M) | ($207M) | ($107M) |
| هامش الربح الصافي % | 20.9% | 16.7% | 14.5% | 13.2% | 10.4% | 7.9% | 38.9% | 4.7% | 4.7% | -88.2% | -940.6% | -449.8% | — | -1579.0% | 9.5% | 48.5% | -23.8% | -1728.3% | -2229.3% | -16936.2% | -273.2% |
| EBITDA | — | $667M | $640M | $416M | $265M | $138M | $148M | $86M | $41M | ($121M) | ($140M) | ($88M) | ($64M) | ($49M) | $2M | $35M | ($12M) | ($48M) | ($74M) | ($203M) | ($103M) |
| ربحية السهم (EPS) | $6.84 | $4.67 | $3.29 | $2.47 | $1.56 | $0.92 | $4.16 | $0.39 | $0.22 | $-1.62 | $-1.63 | $-1.05 | $-0.81 | $-0.69 | $0.08 | $0.67 | $-0.15 | $-1.30 | $-2.30 | $-5.45 | $-2.84 |
| الأسهم القائمة (م) | — | 102M | 104M | 101M | 99M | 98M | 98M | 96M | 95M | 88M | 87M | 84M | 75M | 67M | 67M | 56M | 53M | 39M | 38M | 38M | 38M |
المصدر: التقارير العامة للشركة (SEC). تحقق من SEC EDGAR قبل الاعتماد على أي رقم.
الميزانيات والتدفقات النقدية والبيانات الفصلية والنسب المالية الكاملة في العارض التفاعلي لـ NBIX. /companies/us/NBIX
المعلومات في هذا الموقع لأغراض تعليمية وإعلامية فقط ولا تشكل نصيحة استثمارية. لا تُنشر أسعار مستهدفة أو توصيات.
About TickerBase · Data methodology & sources · Privacy · Terms